Reference no: EM133731869

Question

Ken is a 26-year-old cisgender man with no past medical history presents to your clinic to discuss starting HIV pre-exposure prophylaxis (PrEP). He has multiple male partners, uses condoms intermittently, and was treated for urogenital gonorrhea last month. He heard from a friend that in addition to PrEP there is now a medication that can prevent sexually transmitted infections (STIs) like chlamydia, gonorrhea, and syphilis. You explain that the medication is doxycycline. You shared that the Centers for Disease Control and Prevention (CDC) recommendations are still pending as of March 2024. The DoxyPEP study focused on individuals who were at elevated risk for bacterial STIs, which was defined as having ≥ 1 bacterial STI (chlamydia, gonorrhea or syphilis) in the past 12 months and condomless sex with ≥ 1 male partner in the last 12 months. Which patient population was included in this study? Choose: Individuals with HIV or on PrEP who were assigned male sex at birth Individuals assigned male sex at birth, regardless of HIV status or PrEP usage Individuals with HIV or on PrEP who were assigned female sex at birth Any individual with HIV or on PrEP.